Spyre Therapeutics, INC

Spyre Therapeutics reported positive 12-week induction data from its Phase 2 SKYLINE trial for SPY002 in ulcerative colitis, meeting primary and secondary endpoints with a favorable safety profile.

Spyr Therapeutics amended its license agreement with Paragon Therapeutics to broaden the therapeutic applications for its SPY003 drug beyond inflammatory bowel disease.

Spyre Therapeutics stockholders approved an amended employee stock purchase plan and elected three directors at the 2026 Annual Meeting.

Spyre Therapeutics announced positive Phase 2 data for SPY001 in IBD and provided updates on its rheumatic disease trials, alongside a strengthened balance sheet.

Spyre Therapeutics has successfully closed a public offering of 7,475,000 shares of common stock, generating approximately $463.5 million in gross proceeds.

Spyre Therapeutics announced preliminary cash reserves of approximately $741 million as of March 31, 2026, and terminated its at-the-market prospectus.

Spyre Therapeutics filed its Q1 2026 10-Q, detailing a net loss of $69 million and significant R&D investment, while advancing its IBD and rheumatic disease programs.

Spyre Therapeutics reported a significantly reduced net loss in Q3 2025, driven by a decrease in CVR liability and a gain from an asset sale, while advancing its inflammatory bowel disease and rheumatic disease pipeline into Phase 2 trials.

Spyre Therapeutics reported a net loss of $36.7 million for Q2 2025, advancing its IBD and RD pipeline with positive clinical trial progress and a strong cash position.

Spyre Therapeutics reports its financial results for the first quarter of 2025, highlighting ongoing clinical trials and pipeline development.

Spyre Therapeutics has amended its quarterly report for the period ended September 30, 2024, due to a misapplication of U.S. GAAP related to the calculation of net loss per share and has identified a material weakness in internal control over financial reporting.

Spyre Therapeutics has amended its second-quarter 2024 report to correct a misapplication of U.S. GAAP related to the calculation of net loss per share and has identified a material weakness in internal control over financial reporting.

Spyre Therapeutics, a clinical-stage biotech, reports significant pipeline advancement in IBD and rheumatic diseases, backed by substantial capital raises and positive early clinical data.

Spyre Therapeutics details its financial performance for 2024 and outlines strategic advancements in its IBD and immune-mediated disease programs.

Spyre Therapeutics has filed an amended 10-K report to correct a misapplication of accounting principles related to the calculation of net loss per share and a material weakness in internal control over financial reporting.

Spyre Therapeutics has filed an amendment to its annual report on Form 10-K to include hyperlinks to exhibits that were previously incorporated by reference.

Spyre Therapeutics has transitioned into a preclinical-stage biotech company focused on developing next-generation treatments for inflammatory bowel disease (IBD) following a strategic asset acquisition and the sale of its legacy assets.

Spyre Therapeutics' Chief Financial Officer, Scott L. Burrows, executed a series of stock transactions under a pre-arranged Rule 10b5-1 trading plan.

Sloan Sheldon, Chief Medical Officer of Spyre Therapeutics, Inc., reported transactions involving the sale of common stock and the acquisition of stock options under a Rule 10b5-1 trading plan.

Spyre Therapeutics CEO Cameron Turtle has sold a significant number of company shares through a pre-arranged trading plan.

Spyre Therapeutics, Inc. CFO Scott L. Burrows reports transactions involving common stock and stock options.

Fairmount Funds Management LLC and its affiliates reported the conversion of Series B Preferred Stock into common stock, alongside a sale of common stock.

Director Michael Henderson reported a transaction involving 20,000 shares of Spyre Therapeutics, Inc. common stock on June 22, 2026, executed under a Rule 10b5-1 trading plan.

Spyre Therapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on May 27, 2026, with key proposals including director elections and executive compensation.

Spyre Therapeutics has filed a definitive proxy statement with the Securities and Exchange Commission.

Spyre Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on May 29, 2025, to vote on director elections, executive compensation, and auditor ratification.

Spyre Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on May 13, 2024, to vote on key proposals including director elections, executive compensation, auditor ratification, and stock issuance approvals.

Spyre Therapeutics aims to register the resale of up to 33.4 million shares of its common stock by selling stockholders after recent private placements.

Spyre Therapeutics is filing an amendment to its registration statement for the resale of up to 12 million shares of its common stock by selling stockholders.

Spyre Therapeutics has filed a registration statement for the resale of 12 million shares of common stock by selling stockholders, following a recent private placement that raised $180 million.

Spyre Therapeutics files an amendment to its S-1 registration statement, covering the resale of up to 12 million shares of common stock by selling stockholders.

Spyre Therapeutics completes an asset acquisition to enhance its IBD pipeline and announces key executive appointments and board changes.

Fairmount Funds Management reduced its position in Spyre Therapeutics through a significant block trade following the conversion of preferred shares and a board resignation.

Fairmount Funds Management LLC and its principals have entered into a 60-day lock-up agreement following Spyre Therapeutics' recent underwritten public offering.

Fairmount Funds Management and related parties filed an amended Schedule 13D, reporting a 60-day lock-up agreement on Spyre Therapeutics shares following a public offering.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has reported beneficial ownership of 5.0% of Spyre Therapeutics, Inc.'s common stock as of April 15, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Spyre Therapeutics Inc. following an internal realignment.

The Vanguard Group has reported a 5.08% beneficial ownership stake in Spyre Therapeutics Inc., holding over 3 million shares of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.6% beneficial ownership stake in SPYRE THERAPEUTICS INC's common stock.

Tang Capital Management, Kevin Tang, and affiliated entities have disclosed a passive 5.3% beneficial ownership stake in Spyre Therapeutics, Inc., totaling 3,200,000 shares of common stock.

Venrock Healthcare Capital Partners and affiliated entities have filed an amendment to their Schedule 13G, disclosing a collective beneficial ownership of 4.6% in Spyre Therapeutics, Inc. as of December 31, 2024.